Arganda Del Rey

Researchers are evaluating how well brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone CHP works and how safe it is as a first treatment for adults with CD30-positive peripheral T-cell lymphoma in Spain. This observational study collects information from patients who have already received this treatment as part of routine care to understand real-world outcomes and side effects. The study is led by the Grupo Espaol de Linfomas y Trasplante Autlogo de Mdula sea. Participants received brentuximab vedotin plus CHP as their first-line therapy between January 2019 and September 2024 according to usual medical practice. This study does not assign or change treatments but reviews patient medical records retrospectively to evaluate treatment effectiveness and safety across multiple centers in Spain. During the study, researchers will measure how long participants live without their lymphoma worsening progression-free survival over up to about 68 months. They will also assess how well the treatment shrinks or eliminates lymphoma, overall survival, side effects including nerve problems and low white blood cell counts, and other outcomes like PETCT scan responses and lymphoma subtype impact. Information is gathered from existing medical records, and the study does not involve new treatments or procedures for participants.

This research aims to examine how anxiety and depression symptoms change over the course of cancer and to identify various factors that may predict these changes. These factors include sociodemographic details like age and marital status, clinical features such as tumor location and treatment type, psychological aspects like coping strategies and fear of recurrence, and physical activity levels. The study also explores how these factors relate to the need for and use of psychosocial support services in cancer patients. Participants are adult oncology patients recruited from multiple centers. They are divided into two groups those showing symptoms of anxiety or depression at the start, and those without such symptoms. Data collection occurs at three points baseline diagnosis or treatment start, 3 months, and 6 months. Participants complete standardized questionnaires and undergo medical record reviews to assess psychological symptoms, coping, quality of life, cognitive difficulties, physical activity, nutrition, support needs, and decision-making related to cancer treatment. No experimental treatments are given. During the study, participants will be monitored through self-report questionnaires and medical record reviews at each time point to track symptom changes and associated factors. The main outcomes measured are anxiety and depression symptoms at diagnosis, early evolution at 3 months, and medium-term evolution at 6 months. This observational study helps understand psychological health trajectories in cancer patients and how supportive care is utilized. The total participation spans about six months from diagnosis or treatment initiation.